Immunological Studies on Anti-Aids Drugs in ARC/AIDS
Final rept. 4 Jan 1988-31 Dec 1992
ARIZONA UNIV TUCSON
Pagination or Media Count:
The objectives of the project were to discover and characterize immunomodulatory drugs for patients with HIV-infection and AIDS using in-vitro models and utilizing the murine LP-BM5 MAIDS model. Drugs were supplied, coded by number and were tested using those model systems. Diethyldithiocarbamate and Imexon were found to be highly active in the in-vivo system. Imexon was synergistic with AZT. Imexon in addition to activity in LP-BM5 was also active in the prevention of the development of lymphoma in the SCID mouse given human PBMC. Imexon was also found to be active against B cell malignancies in vitro. Imexon was recommended to the NIAID for development as a drug for HIV. Other compounds were found to beactive in-vitro but were not further developed because of the early termination of the project. The activity was mainly in the augmentation of mitogen responses or in the augmentation of NK activity. These included compounds 1758, 4728, and 8522. The investigator feels continued work on immunomodulation in AIDS is justified. AIDS, HTLV-III, Volunteers, Lab animals, RA I, Drug development, BD, Lymphocytes, Antiviral, Immunomodulators.
- Medicine and Medical Research